Ernexa Therapeutics Inc.

ERNANASDAQHealthcare● Active

$7.62

+$0.23(+3.11%)

Market Cap$2393625

P/E Ratio—

52W High$71.5

52W Low$3.18

Avg Volume1.6M

Open$7.84

Beta2.50

Overview

Ernexa Therapeutics Inc. (ERNA) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

ERNA · free cash flow · updated Jun 9, 2026

Core FCF metrics

ERNA · FCF · TTM · margin & CAGR

Free cash flow was −$7.1M for FY2025 (fiscal year ending 2025-12-31), up 56.5% year-over-year

FY2025 Free Cash Flow−$7.1M▲ +56.5% YoY

Trailing 12M (TTM)−$7.3Mtrailing 4 quarters sum

FCF Margin——

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 9, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

ERNA · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest−$7.0M(0M)−$7.1M▲ +56.5%—

FY2024−$15.8M(0M)−$16.2M▲ +20.7%—

FY2023−$20.4M(0M)−$20.4M▲ +4.0%—

FY2022−$21.0M(0M)−$21.3M▲ +10.0%—

FY2021−$23.5M(0M)−$23.6M▼ 190.4%—

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

ERNA · P/FCF · FCF yield · FCF per share

Ernexa Therapeutics Inc. (ERNA) reported negative free cash flow of −$0.01B. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

ERNA · cash flow statement · operating / investing / financing

For FY2025, Ernexa Therapeutics Inc. generated −$7.0M in operating cash flow and spent 0M in capital expenditures, yielding −$7.1M in free cash flow.

Operating Activities

−$7.0M

Cash from core business operations

2025-12-31

Investing Activities

−$0.0M

CapEx, acquisitions & investments

2025-12-31

Financing Activities

+$7.2M

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF (−$7.0M) − |CapEx| (0M) = FCF (−$7.1M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

ERNA vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Ernexa Therapeutics Inc.YOU

ERNA

−$7.1M+56.5%—

Loss

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Ernexa Therapeutics Inc. (ERNA) reported free cash flow of −$7.1M for FY2025 (fiscal year ending 2025-12-31), up 56.5% year-over-year.

Based on available data, Ernexa Therapeutics Inc. has maintained positive free cash flow for at least 1 fiscal year(s). FCF peaked at $1.6M in FY2019.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

ERNA free cash flow · 8 questions

Ernexa Therapeutics Inc. free cash flow was −$7.1M for FY2025, up 56.5% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$7.3M.

ERNA free cash flowERNA FCFERNA FCF 2025ERNA free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Ernexa Therapeutics Inc. · Ernexa Therapeutics Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 9, 2026